12 June 2013
Blueprint Genetics has launched a new genetic testing technology for professional use in hospitals. The gene sequencing technology is based on Stanford University research and can effectively analyse rare hereditary human diseases. The company started its operations in 2012 in Helsinki.
The tests of Blueprint Genetics enable efficient diagnosis of difficult hereditary diseases. Today there are almost 4000 recognized diseases with a genetic background. The results of genetic tests will help physicians in reaching their diagnoses, predicting the course of the disease, choosing treatments, and efficient screening of relatives. The first tests of Blueprint Genetics focus on hereditary cardiovascular diseases.
The company aims to bring genetic diagnostics into the daily routines of healthcare organizations by lowering the barrier to start using genetic testing. This will be enabled by offering tests that are more comprehensive, more cost-effective and faster than existing tests. The geneticists and clinicians at Blueprint Genetics will interpret the test results and give statements directly to the treating physicians within three weeks from sample reception.
Blueprint Genetics targets international diagnostics markets and will begin its operations in the EU area. The international recommendations for the use of genetic diagnostics are increasing rapidly and current research advocates comprehensive testing for hereditary diseases. According to Blueprint Genetics, there have never been so comprehensive, or easy-to-use tests available for a price level that is feasible for clinical use.
The company has a strong background in medical genetics research. “Finland is a great place to start an international genetics growth company. We have a huge amount of knowledge and resources in Finland and the genetics research is globally recognized,” says Tommi Lehtonen, CEO of Blueprint Genetics.
Blueprint Genetics Oy